For most people treated with medication for Graves' disease, the condition returns within 10 years—nearly 8 in 10 patients experience a recurrence, suggesting drug therapy rarely provides a permanent cure.
Claim Context
After antithyroid drug treatment for Graves' disease, the cumulative relapse rate reaches 78.9% at 10 years, indicating that long-term remission is uncommon with drug therapy alone.
“Los resultados mostraron una probabilidad de recidiva del hipertiroidismo del 42,9% al año, del 59,8% a los 3 años, del 67,9% a los 5 años y del 78,9% a los 10 años.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether the 78.9% 10-year relapse rate is consistent across populations, treatment durations, and drug regimens, and whether it has changed with modern protocols.
A systematic review and meta-analysis of all prospective cohort studies reporting 10-year relapse rates after antithyroid drug discontinuation in Graves' disease, stratified by treatment duration (>18 months vs. ≤18 months), drug type (methimazole vs. PTU), and TBII status, with pooled estimates and heterogeneity analysis.
An RCT could compare relapse rates between different drug regimens (e.g., long-term low-dose vs. short-term high-dose) to determine if treatment duration modifies the 10-year relapse rate.
A multicenter double-blind RCT of 600 adults with Graves' disease, randomized to 18 months of methimazole (5 mg/day) versus 36 months (2.5 mg/day), with primary outcome of sustained remission at 10 years defined as euthyroidism without medication and TBII <1.0 IU/L.
A prospective cohort study could replicate the 10-year relapse rate in a contemporary population to assess whether it remains valid with modern diagnostic and treatment standards.
A prospective multicenter cohort of 1000 adults with newly diagnosed Graves' disease, treated with methimazole for 18–24 months, followed for 10 years with annual thyroid function and TBII testing, using Kaplan-Meier analysis to estimate relapse rates.
A case-control study could compare characteristics of patients who relapsed at 10 years versus those who remained in remission to identify potential risk factors.
A matched case-control study of 300 patients: 150 with relapse at 10 years and 150 matched controls (age, sex, treatment duration) who remained euthyroid, comparing baseline goiter volume, TBII levels, HLA type, and smoking history.
A cross-sectional study could estimate the proportion of patients with prior antithyroid treatment who currently have relapsed disease, but cannot track progression over time.
A cross-sectional survey of 1000 adults with a history of Graves' disease treated with antithyroid drugs, asking about relapse status and time since treatment, with thyroid function testing to confirm current status.